Health Catalyst Q4 Earnings Call Highlights

Health Catalyst Unveils Mixed Q4 2025 Financial Results

Health Catalyst, a key player in healthcare data analytics, released its fourth-quarter and full-year 2025 earnings, painting a picture of resilience amid challenges.

For the quarter ending December 2025, the company posted revenue of $74.8 million, marking a 6.1% drop from the previous year. This decline stemmed largely from reduced professional services revenue, which fell due to cuts in full-time employee offerings and the end of unprofitable pilot programs. Technology revenue, however, remained steady at $51.9 million.

Despite the revenue dip, there were bright spots. Adjusted EBITDA surged 75% year-over-year to $13.8 million, and the adjusted gross margin improved significantly to 53.5%, up 690 basis points. These gains reflect ongoing restructuring efforts aimed at streamlining operations and boosting efficiency.

Full-Year Performance Shows Steady Progress Amid Headwinds

Looking at the entire 2025 fiscal year, Health Catalyst achieved total revenue of $311.1 million, a modest 1% increase over 2024. This growth was driven by a 7% rise in technology revenue to $208.3 million, offsetting weaker professional services.

Adjusted EBITDA for the year jumped 59% to $41.4 million, highlighting improved profitability metrics. The full-year adjusted gross margin reached 51.1%, with technology margins at a robust 67.4% and professional services at 18.3%. Operating expenses also came down, dropping to 38% of revenue from 40% the year prior.

On the balance sheet, the company maintains a solid current ratio of 1.88 and a manageable debt-to-equity ratio of 0.52. Free cash flow turned positive at $4.5 million in the quarter, a welcome shift from prior losses. Yet, net losses widened dramatically in Q4 to $91 million, underscoring persistent challenges in achieving overall profitability, with a net margin still in negative territory at -34.05%.

New CEO Charts Path Forward with Strategic Focus

Under new CEO Benjamin Albert, Health Catalyst is embarking on a "back-to-basics" strategy to sharpen its competitive edge. The leadership team is prioritizing operational efficiency, technology bookings expansion, and stronger client retention.

We closed 2025 with solid performance across our business, including total revenue of $311.1 million and Adjusted EBITDA of $41.4 million. In 2026, we are focused on the future and on positioning Health Catalyst for long-term success. As I continue to assess the business, I see both meaningful opportunities and clear areas where we must improve.

Looking ahead, Q1 2026 guidance came in below analyst expectations, with projected revenue of $69 million and adjusted EBITDA of $7.5 million. This conservative outlook reflects caution amid market uncertainties, including analyst concerns over the company's turnaround efforts. Stock reactions were muted, with shares dipping post-earnings, as investors weigh the mixed signals.

Albert's emphasis on cost alignment with revenue and investments in high-margin technology positions the firm for potential recovery. Gross margins continue to expand, and operating leverage is a core focus, even as revenue per share trends downward.

In summary, Health Catalyst's Q4 2025 earnings reveal a company navigating revenue softness and deep losses while making strides in margins and efficiency. Full-year results offer optimism, bolstered by new leadership's strategic pivot toward sustainable growth in healthcare analytics. Investors will watch closely as 2026 unfolds.